Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

NCT05480865 is registered in ClinicalTrials.gov with Navire Pharma Inc., a BridgeBio company as lead sponsor.

NCT NCT05480865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Phase
Phase 1
Overall status
Terminated
Start date
July 6, 2022
Completion date
August 22, 2024
Enrollment
28 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc, metastatic solid tumor, non small cell lung cancer, solid tumor, adult